Publisher: Spandidos Publications
E-ISSN: 1792-1015|9|5|1597-1604
ISSN: 1792-0981
Source: Experimental and Therapeutic Medicine, Vol.9, Iss.5, 2015-01, pp. : 1597-1604
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Elevated expression of glyceraldehyde3phosphate dehydrogenase (GAPDH) has been reported in different human malignancies. To understand its role in hepatitis B virus (HBV) infection-associated hepatocellular carcinoma (HCC), the expression of GAPDH was quantitatively measured in a cohort of 72 male HCC patients without preoperative treatment, all with evidence of chronic HBV infection. Using Cterminal banding protein 1 (CTBP1) or hypoxanthine phosphoribosyltransferase 1 (HPRT1) as reference genes, the level of GAPDH mRNA in tumor tissue was found to be significantly higher compared with that in paired non tumor tissues (P=0.0087 for CTBP1; P=0.0116 for HPRT1). Accordingly, compared with the non-tumor tissue, 37.5% (27/72) of patients' tumor tissues had a more than 2fold increase of GAPDH expression. Furthermore, following knockdown GAPDH expression via siRNA transient transfection, HepG2 cells exhibited enhanced resistance to cytosine arabinoside (IC50, 308.28 µM vs. 67.68 µM in the control; P=0.01). Notably, higher GAPDH expression was significantly associated with lower liver fibrosis score (P=0.0394) and a tendency towards higher survival rates for patients with HCC. To the best of our knowledge, the present study is the first study to report that the elevated expression levels of GAPDH in HCC tumor tissue may be relevant to an improved fibrosis score and survival probability in male patients with HBV infection; however, the underlying mechanism requires further investigation.
Related content
By Kim Jong Kwon Choon Joh Jae-Won Park Jae Lee Joon Kim Sung Paik Seung Park Cheol Yoo Byung
Annals of Surgical Oncology, Vol. 21, Iss. 2, 2014-02 ,pp. :